CloneID: mab 911
Buffer Composition: PBS with 0.02% Proclin 300.
Chimeric Use Statement: This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format for improved compatibility with existing reagents assays and techniques.
Available Custom Conjugation Options: AP, HRP, Fluorescein, APC, PE, Biotin Type A, Biotin Type B, Streptavidin, FluoroProbes 647H, Atto488, APC/Cy7, PE/Cy7
Uniprot Accession No.: P01138
Specificity Statement: The antibody is specific for NGF. The NGF epitope is composed of β-strand segments from both NGF monomers. NGF is involved primarily in the growth, as well as the maintenance, proliferation, and survival of nerve cells (neurons).
Application Notes (Clone): The specificity of the original format of the antibody to NGF was confirmed by ELISA analysis (EC50 = 0.37 nM). The antibody was evaluated for its ability to block the binding of hNGF to the TrkA and p75 NGF receptors in various in vitro assays, such as blocking of TrkA autophosphorylation and blocking of NGF-dependent survival of dorsal root ganglion sensory neurons. The antibody was a potent blocker of all activities (Hongo et al., 2000; PMID: 10952410). In vivo administration of the antibody significantly reduces bone cancer pain behaviors (Sevcik et al., 2005; PMID: 15836976 and Halvorson et al., 2005; PMID: 16230406 and Buehlmann et al., 2019; PMID: 30161041) and fracture pain-related behaviors (Koewler et al., 2007; PMID: 17638576). The structure of Nerve Growth factor in complex with the Fab fragment was determined. Library Scanning Mutagenesis method was used to convert the original antibody in the humanized antibody tanezumab. The antibody bound human and murine NGF with high affinity (KD ~10 nM). Tanezumab and the original antibody blocked both TrkA and p75NTR binding to NGF and inhibited NGF-dependent neuron survival. Tanezumab inhibited NGFdependent survival with an IC50 of 15 pM; under the same conditions, 911 inhibited NGF with an IC50 of 400 pM (La Porte et al., 2014; PMID: 24830649). Preventative and therapeutic treatment with the antibody significantly prevented, or reversed, MIA-induced pain behaviour in osteoarthritis (Xu et al., 2016; PMID: 27208420).
Deutsch
English
